- Home
- LXRX
as 10-28-2025 9:35am EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 552.4M | IPO Year: | 2000 |
| Target Price: | $3.23 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.08 | Next Earning Date: | 11-11-2025 |
| Revenue: | $58,432,000 | Revenue Growth: | 1504.83% |
| Revenue Growth (this year): | 66.55% | Revenue Growth (next year): | -75.86% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
13 days ago
How Viatris Prevents and Manages NCDs
GlobeNewswire
14 days ago
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
GlobeNewswire
20 days ago
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
MT Newswires
a month ago
Lexicon Pharmaceuticals Says FDA Delays Feedback on Zynquista Data
GlobeNewswire
a month ago
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
GlobeNewswire
2 months ago
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
MT Newswires
2 months ago
Lexicon Pharmaceuticals Submits Additional Data to US FDA for Zynquista
GlobeNewswire
2 months ago
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.